Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology - Tập 13 Số 2 - Trang 181-188 - 2012
Yong‐Seok Jee1, Se Hoon Park, Heung Moon Chang, Jun Suk Kim, Hye Jin Choi, Myung Ah Lee, Joung Soon Jang, Joung Soon Chang, Hei Cheul Jeung, Jung Hun Kang, Hyun Woo Lee, Dong Bok Shin, Hye Jin Kang, Jong‐Mu Sun, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim
1Division of Haematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Centre, Seoul, South Korea.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Won, 2009, Nationwide cancer incidence in Korea, 2003–2005, Cancer Res Treat, 41, 122, 10.4143/crt.2009.41.3.122

Glimelius, 1996, Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer, Ann Oncol, 7, 593, 10.1093/oxfordjournals.annonc.a010676

Thongprasert, 2005, The role of chemotherapy in cholangiocarcinoma, Ann Oncol, 16, ii93, 10.1093/annonc/mdi712

Valle, 2009, Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study—The UK ABC-01 Study, Br J Cancer, 101, 621, 10.1038/sj.bjc.6605211

Valle, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, 362, 1273, 10.1056/NEJMoa0908721

Andre, 2004, Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study, Ann Oncol, 15, 1339, 10.1093/annonc/mdh351

Harder, 2006, Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer, Br J Cancer, 95, 848, 10.1038/sj.bjc.6603334

Jang, 2010, Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial, Cancer Chemother Pharmacol, 65, 641, 10.1007/s00280-009-1069-7

Eckel, 2007, Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials, Br J Cancer, 96, 896, 10.1038/sj.bjc.6603648

Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525

Philip, 2006, Phase II study of erlotinib in patients with advanced biliary cancer, J Clin Oncol, 24, 3069, 10.1200/JCO.2005.05.3579

Lubner, 2010, Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study, J Clin Oncol, 28, 3491, 10.1200/JCO.2010.28.4075

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Leong, 2010, Outcomes from combined chemoradiotherapy in unresectable and locally advanced resected cholangiocarcinoma, J Gastrointest Cancer

Golfieri, 2004, Unresectable hilar cholangiocarcinoma: multimodality treatment with percutaneous and intraluminal plus external radiotherapy, J Chemother, 16, 55, 10.1080/1120009X.2004.11782386

Morganti, 2000, Combined modality treatment in unresectable extrahepatic biliary carcinoma, Int J Radiat Oncol Biol Phys, 46, 913, 10.1016/S0360-3016(99)00487-3

Yoshikawa, 2008, Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma, Br J Cancer, 98, 418, 10.1038/sj.bjc.6604129

Kim, 2011, Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy, Mol Cancer Ther, 10, 1993, 10.1158/1535-7163.MCT-11-0269

Zhu, 2010, Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study, Lancet Oncol, 11, 48, 10.1016/S1470-2045(09)70333-X

Gruenberger, 2010, Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study, Lancet Oncol, 11, 1142, 10.1016/S1470-2045(10)70247-3

Wiedmann, 2010, Molecular targeted therapy of biliary tract cancer—results of the first clinical studies, Curr Drug Targets, 11, 834, 10.2174/138945010791320818

Malka, 2009, A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial, Proc Am Soc Clin Oncol, 27

Sharma, 2010, Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study, J Clin Oncol, 28, 4581, 10.1200/JCO.2010.29.3605

Park, 2006, Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma, Cancer, 106, 361, 10.1002/cncr.21621